Back to results
US 4,868,107 AGranted
Method for detecting antibodies against neuropeptides and drugs in human body fluid
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorBenjamin F. Roy, III
Life of this patent
Estimating the term…
Abstract
An immunochemical assay, particularly an enzyme-linked immunosorbent assay has been developed to detect in a sample of human body fluid the presence of antibodies against neuropeptides or drugs. The assay makes it possible to correlate and diagnose psychobiological disorders related to the alteration in the normal level of neuropeptides or their receptors.
Claims2
A method for detecting in a sample of human body fluid the presence of specific antibodies against brain peptides or brain drugs comprising the steps of:
- (a) coating a multiwell plate with a solution of neuropeptide or brain drug to be detected, by incubating the plate for more than 24 hours with said solution at about 0.degree. to 4.degree. C. without a blocking step;
- (b) then allowing a sample of immunoglobulin containing human body fluid in which the presence of antibody to th e neuropeptide or brain drug is to be detected, to react with the coated plate in humidified air containing about 5-7% CO.sub.2 for about 1.5 to 3 hours at 37.degree. C.;
- (c) then washing the plate with a buffered detergent more than 5 times to remove unbound material from the plate;
- (d) then allowing anti-human antibody conjugated with a marker entity to react for about 1.5 to 3 hours in humidified air containing about 5-7% CO.sub.2 at about 37.degree. C. with the washed plate of step (c) to allow binding of the conjugated-antibody with the human antibody bound to the neuropeptide or brain drug;
- (e) then removing the unreacted material from the plate by washing more than 5 times as in step (c);
- (f) then determining the presence of the marker by enzymatic, spectrophotometric, fluorscentphotometric or radioisotopic assay and comparing with a control sample treated identically as in step (a) thru (e), a reading above the control being indicative of the presence of antibody against the neuropeptide or the brain drug.
3 more elements
Dependencies are inferred from the claim text.